S&P 500   4,471.37 (+0.75%)
DOW   35,294.76 (+1.09%)
QQQ   368.94 (+0.63%)
AAPL   144.84 (+0.75%)
MSFT   304.21 (+0.48%)
FB   324.76 (-1.15%)
GOOGL   2,827.36 (+0.15%)
TSLA   843.03 (+3.02%)
AMZN   3,409.02 (+3.31%)
NVDA   218.62 (+0.53%)
BABA   168.00 (+0.73%)
NIO   37.71 (+3.94%)
CGC   13.35 (-2.55%)
GE   104.41 (+1.63%)
MU   67.68 (-0.18%)
AMD   112.12 (+0.12%)
T   25.70 (+0.31%)
F   15.70 (+1.62%)
ACB   7.03 (-3.17%)
DIS   176.46 (+1.18%)
PFE   41.49 (-0.43%)
BA   217.04 (-0.18%)
AMC   40.74 (+1.67%)
S&P 500   4,471.37 (+0.75%)
DOW   35,294.76 (+1.09%)
QQQ   368.94 (+0.63%)
AAPL   144.84 (+0.75%)
MSFT   304.21 (+0.48%)
FB   324.76 (-1.15%)
GOOGL   2,827.36 (+0.15%)
TSLA   843.03 (+3.02%)
AMZN   3,409.02 (+3.31%)
NVDA   218.62 (+0.53%)
BABA   168.00 (+0.73%)
NIO   37.71 (+3.94%)
CGC   13.35 (-2.55%)
GE   104.41 (+1.63%)
MU   67.68 (-0.18%)
AMD   112.12 (+0.12%)
T   25.70 (+0.31%)
F   15.70 (+1.62%)
ACB   7.03 (-3.17%)
DIS   176.46 (+1.18%)
PFE   41.49 (-0.43%)
BA   217.04 (-0.18%)
AMC   40.74 (+1.67%)
S&P 500   4,471.37 (+0.75%)
DOW   35,294.76 (+1.09%)
QQQ   368.94 (+0.63%)
AAPL   144.84 (+0.75%)
MSFT   304.21 (+0.48%)
FB   324.76 (-1.15%)
GOOGL   2,827.36 (+0.15%)
TSLA   843.03 (+3.02%)
AMZN   3,409.02 (+3.31%)
NVDA   218.62 (+0.53%)
BABA   168.00 (+0.73%)
NIO   37.71 (+3.94%)
CGC   13.35 (-2.55%)
GE   104.41 (+1.63%)
MU   67.68 (-0.18%)
AMD   112.12 (+0.12%)
T   25.70 (+0.31%)
F   15.70 (+1.62%)
ACB   7.03 (-3.17%)
DIS   176.46 (+1.18%)
PFE   41.49 (-0.43%)
BA   217.04 (-0.18%)
AMC   40.74 (+1.67%)
S&P 500   4,471.37 (+0.75%)
DOW   35,294.76 (+1.09%)
QQQ   368.94 (+0.63%)
AAPL   144.84 (+0.75%)
MSFT   304.21 (+0.48%)
FB   324.76 (-1.15%)
GOOGL   2,827.36 (+0.15%)
TSLA   843.03 (+3.02%)
AMZN   3,409.02 (+3.31%)
NVDA   218.62 (+0.53%)
BABA   168.00 (+0.73%)
NIO   37.71 (+3.94%)
CGC   13.35 (-2.55%)
GE   104.41 (+1.63%)
MU   67.68 (-0.18%)
AMD   112.12 (+0.12%)
T   25.70 (+0.31%)
F   15.70 (+1.62%)
ACB   7.03 (-3.17%)
DIS   176.46 (+1.18%)
PFE   41.49 (-0.43%)
BA   217.04 (-0.18%)
AMC   40.74 (+1.67%)
NASDAQ:CODX

Co-Diagnostics Stock Forecast, Price & News

$8.38
-0.25 (-2.90 %)
(As of 10/15/2021 04:00 PM ET)
Add
Compare
Today's Range
$8.38
$8.81
50-Day Range
$8.38
$11.38
52-Week Range
$7.01
$20.69
Volume347,141 shs
Average Volume1.17 million shs
Market Capitalization$242.10 million
P/E Ratio5.41
Dividend YieldN/A
Beta-3.17
30 days | 90 days | 365 days | Advanced Chart
Receive CODX News and Ratings via Email

Sign-up to receive the latest news and ratings for Co-Diagnostics and its competitors with MarketBeat's FREE daily newsletter.


Co-Diagnostics logo

About Co-Diagnostics

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight H. Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CODX
Employees
37
Year Founded
N/A

Sales & Book Value

Annual Sales
$74.55 million
Cash Flow
$1.47 per share
Book Value
$2.36 per share

Profitability

Net Income
$42.48 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$242.10 million
Next Earnings Date
11/15/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.92 out of 5 stars

Medical Sector

673rd out of 1,361 stocks

Surgical & Medical Instruments Industry

66th out of 124 stocks

Analyst Opinion: 3.3Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.3 5 -4 -3 -2 -1 -












Co-Diagnostics (NASDAQ:CODX) Frequently Asked Questions

Is Co-Diagnostics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Co-Diagnostics stock.
View analyst ratings for Co-Diagnostics
or view top-rated stocks.

What stocks does MarketBeat like better than Co-Diagnostics?

Wall Street analysts have given Co-Diagnostics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Co-Diagnostics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Co-Diagnostics?

Co-Diagnostics saw a decrease in short interest in August. As of August 31st, there was short interest totaling 2,390,000 shares, a decrease of 23.4% from the August 15th total of 3,120,000 shares. Based on an average trading volume of 1,280,000 shares, the days-to-cover ratio is presently 1.9 days.
View Co-Diagnostics' Short Interest
.

When is Co-Diagnostics' next earnings date?

Co-Diagnostics is scheduled to release its next quarterly earnings announcement on Monday, November 15th 2021.
View our earnings forecast for Co-Diagnostics
.

How were Co-Diagnostics' earnings last quarter?

Co-Diagnostics, Inc. (NASDAQ:CODX) issued its earnings results on Thursday, August, 12th. The company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.11. The business had revenue of $27.36 million for the quarter, compared to analysts' expectations of $21 million. Co-Diagnostics had a trailing twelve-month return on equity of 65.33% and a net margin of 47.98%.
View Co-Diagnostics' earnings history
.

How has Co-Diagnostics' stock price been impacted by Coronavirus?

Co-Diagnostics' stock was trading at $13.19 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CODX stock has decreased by 36.5% and is now trading at $8.38.
View which stocks have been most impacted by COVID-19
.

What guidance has Co-Diagnostics issued on next quarter's earnings?

Co-Diagnostics issued an update on its third quarter 2021 earnings guidance on Thursday, September, 9th. The company provided EPS guidance of $0.190-$0.220 for the period, compared to the Thomson Reuters consensus estimate of $0.180. The company issued revenue guidance of $23 million-$25 million, compared to the consensus revenue estimate of $18.12 million.

What price target have analysts set for CODX?

2 Wall Street analysts have issued 1-year price objectives for Co-Diagnostics' shares. Their forecasts range from $16.00 to $20.00. On average, they expect Co-Diagnostics' stock price to reach $18.00 in the next year. This suggests a possible upside of 114.8% from the stock's current price.
View analysts' price targets for Co-Diagnostics
or view top-rated stocks among Wall Street analysts.

Who are Co-Diagnostics' key executives?

Co-Diagnostics' management team includes the following people:
  • Dwight Howard Egan, Chairman, President & Chief Executive Officer
  • Brian L. Brown, Chief Financial Officer & Secretary
  • Jesse Montgomery, Chief Scientific Officer
  • Reed L. Benson, General Counsel (LinkedIn Profile)

What other stocks do shareholders of Co-Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Moderna (MRNA), Vaxart (VXRT), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), iBio (IBIO), Advanced Micro Devices (AMD), Pfizer (PFE) and Johnson & Johnson (JNJ).

When did Co-Diagnostics IPO?

(CODX) raised $9 million in an IPO on Thursday, July 13th 2017. The company issued 1,300,000 shares at $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities acted as the underwriters for the IPO.

What is Co-Diagnostics' stock symbol?

Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX."

Who are Co-Diagnostics' major shareholders?

Co-Diagnostics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Prairiewood Capital LLC (0.21%) and NEXT Financial Group Inc (0.01%). Company insiders that own Co-Diagnostics stock include Dwight H Egan, Eugene Durenard, Reed L Benson and Richard S Serbin.
View institutional ownership trends for Co-Diagnostics
.

Which major investors are buying Co-Diagnostics stock?

CODX stock was acquired by a variety of institutional investors in the last quarter, including Prairiewood Capital LLC, and NEXT Financial Group Inc.
View insider buying and selling activity for Co-Diagnostics
or or view top insider-buying stocks.

How do I buy shares of Co-Diagnostics?

Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Co-Diagnostics' stock price today?

One share of CODX stock can currently be purchased for approximately $8.38.

How much money does Co-Diagnostics make?

Co-Diagnostics has a market capitalization of $242.10 million and generates $74.55 million in revenue each year. The company earns $42.48 million in net income (profit) each year or $1.52 on an earnings per share basis.

How many employees does Co-Diagnostics have?

Co-Diagnostics employs 37 workers across the globe.

What is Co-Diagnostics' official website?

The official website for Co-Diagnostics is www.codiagnostics.com.

Where are Co-Diagnostics' headquarters?

How can I contact Co-Diagnostics?

Co-Diagnostics' mailing address is 2401 SOUTH FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT, 84124. The company can be reached via phone at (801) 438-1036 or via email at [email protected].


This page was last updated on 10/15/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.